GlassScriptPhysician profile
Daniel Lo Verde
NPI 1801178645
$13,849.42
in general payments reported to CMS, 2019-2025
14 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $4,080 · 2023: $7,771 · 2024: $232 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,579 · Travel and Lodging: $1,794 · Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,579.00 |
| Travel and Lodging | $1,793.88 |
| Food and Beverage | $1,215.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $11,347.82 | 2022-2023 | Lifesparc, Protekduo |
| Abiomed | $1,330.27 | 2021-2025 | Impella |
| Becton, Dickinson and Company | $636.20 | 2025 | |
| Glaxosmithkline, LLC. | $142.26 | 2023-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $85.62 | 2023-2024 | Fasenra, Airsupra, Tezspire |
| Nuwellis, INC. | $60.95 | 2022-2024 | Aquadex Smartflow Console |
| Merck Sharp & Dohme LLC | $59.89 | 2023-2024 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.33 | 2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Verona Pharma, INC. | $42.61 | 2025 | Ohtuvayre |
| Getinge USA Sales, LLC | $28.01 | 2024 | Cardiohelp |
| Harmony Biosciences LLC | $25.95 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $16.83 | 2025 | Lumryz |
| Edwards Lifesciences Corporation | $15.83 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.85 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lo Verde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.